Furthermore, nearly 3–5% of prostate cancer cases are associated with a deficiency in MMR genes (MSH2, MSH6, PMS2, MLH1), resulting in hypermutation and MSI [74]. This evidence concerns the gene PMS2 and prostate carcinoma.